Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.

Our proprietary delivery system allows a class of existing high potency oncology drugs to be dosed orally to improve patient outcomes and quality of life.

Our Src Kinase Inhibitors also bind to a novel site on tubulin heterodimers thereby broadening their anti-tumor activity beyond that provided by Src inhibition alone.

Transformative, oncology-focused and highly synergistic pipeline with late stage product candidates.

Important Information

Click Here for Important information for Health Care Providers regarding Sodium Bicarbonate Injection
Click Here for Athenex Anti-Capital Punishment Statement

Athenex Receives Positive Feedback from FDA on the Design of Phase III Clinical Trial for Oraxol

January 16, 2018

BUFFALO, N.Y., Jan. 16, 2018 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the United States Food and Drug Administration (“FDA”) has provided positive feedback on the design of the currently ongoing Phase III Clinical Trial for Oraxol, an innovative oral formulation of paclitaxel combined with HM30181A (a novel P-gp inhibitor). Specifically, the FDA indicated that if the study meets the primary endpoint with an acceptable Benefit/Risk profile, it could be adequate as a single comparative trial to support registration of Oraxol for a metastatic breast cancer indication in the United States.

Read more

Athenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical Trials

January 08, 2018

BUFFALO, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Chinese FDA has allowed the Investigational New Drug (IND) application for Oraxol, an oral formulation of paclitaxel. As previously announced, the IND application was submitted to the Chinese FDA in June 2017. In May 2017, Athenex, together with its partner Xiangxue Pharmaceuticals, also obtained Chinese FDA IND allowance of KX-02 in order to begin Phase I clinical trials for Glioblastoma Multiforme (GBM) in China.

Read more

Athenex Receives Promising Innovative Medicine Designation from the United Kingdom MHRA for Oraxol, An Innovative Oral Form of Paclitaxel

December 27, 2017

BUFFALO, N.Y., Dec. 27, 2017 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) granted a Promising Innovative Medicine (PIM) designation for Oraxol in the treatment of paclitaxel-responsive cancers.

Read more

Almirall and Athenex announce strategic partnership for the treatment of actinic keratosis

December 11, 2017

BARCELONA, Spain and BUFFALO, N.Y., Dec. 11, 2017 (GLOBE NEWSWIRE) — Almirall, S.A (ALM)a global skin-health focused pharmaceutical company, today announced an agreement with Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, to further develop and commercialize KX2-391 for the treatment of actinic keratosis and other skin conditions.

Subject to the terms and conditions of the License Agreement, Athenex will grant to Almirall an exclusive license under the Athenex IP to research, develop and commercialize KX2-391 in the United States of America and European countries, including Russia.

Read more

Athenex Announces Positive Recommendations from the Drug Safety Monitoring Board to Continue the Oraxol Phase III Program

October 05, 2017

BUFFALO, N.Y., Oct. 05, 2017 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that a planned interim analysis of the Oraxol 001 Phase III Clinical Trial has been conducted and reviewed by an independent Drug Safety Monitoring Board (DSMB). The DSMB unanimously recommended continuation of the study. The DSMB was impressed by the conduct of the study in achieving a good overall response rate. The DSMB was reassured by the expected difference in safety profile between Oraxol and IV paclitaxel. In particular, the adverse event of painful neuropathy was uncommon with Oraxol treatment. The DSMB encouraged the rapid patient recruitment toward the scheduled second interim analysis at 180 patients.

Read more

Athenex IPO on the NASDAQ Stock Market, June 14, 2017

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.   Learn More

Photography by Christopher Galluzzo / Nasdaq, Inc.
Photography by Christopher Galluzzo / Nasdaq, Inc.

Governor Cuomo Announces Major Expansion of Athenex — Creating 1,400 Jobs in Western New York

Athenex (formerly Kinex) to invest $1.62 billion in drug discovery and advanced manufacturing partnership, creating 900 jobs in Dunkirk and 500 jobs in Buffalo over the next ten years.

State investing $225 million to support the Buffalo Medical Innovation and Commercialization Hub and help create new opportunities for the region.

Governor Andrew M. Cuomo recently announced a major expansion of Athenex that will create 1,400 jobs throughout Western New York. This announcement, made possible by a partnership with the SUNY Polytechnic Institute, includes a major expansion of Athenex’s North American headquarters at the Conventus Building in Buffalo, as well as the creation of a state-of-the-art, 300,000 square foot manufacturing facility in Dunkirk.

Read more

Rendering of new 300,000 square foot facility
Rendering of new 300,000 square foot facility

Athenex Completes Public/Private Partnership Agreement with Chongqing, China To Construct Two New Pharmaceutical Manufacturing Plants

Athenex recently announced the completion and execution of a definitive agreement with the Banan District in Chongqing, China to construct two separate pharmaceutical manufacturing plants on Banan sites already identified and selected by Athenex management. Under the terms of the agreement, Banan will provide the funding for the land and construction of the manufacturing plants according to Athenex specifications, and Athenex will equip the facilities.

Read more